Summit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00. In the quarter to June 2026, EPS grew 63.2% and free cash flow fell 112.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SMMT
Summit Therapeutics PLC (SMMT) EV/Sales
As of 16 October 2026, Summit Therapeutics PLC (SMMT) trades at a EV/Sales of 15,310×. Over the past ten years it has ranged from −31.9× (February 2020) to 38,051× (April 2025); the current reading is higher than 84% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 1,153× | 637.85% |
| FY2021 | 156× | (48.41%) |
| FY2020 | 303× | — |
| FY2019 | −19.1× | — |
| FY2019 | −0.1× | — |
| FY2018 | 0.1× | (99.77%) |
| FY2018 | 26.0× | (24.10%) |
| FY2017 | 34.3× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | 1,153× | 625.22% |
| Sep 2022 | 159× | 200.69% |
| Jun 2022 | 52.9× | (62.86%) |
| Mar 2022 | 142× | (8.89%) |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | 3.4× |
| BMRN BioMarin Pharmaceutical Inc. compare | 4.1× |
| TECH Bio-Techne Corp compare | 9.3× |
| HALO Halozyme Therapeutics, Inc. compare | 9.7× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 9.8× |
| CORT Corcept Therapeutics Incorporated compare | 13.6× |
| BBIO BridgeBio Pharma, Inc. compare | 19.9× |
| IBRX ImmunityBio, Inc. compare | 63.6× |
| SMMT Summit Therapeutics PLC | 15,310× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)